Literature DB >> 27106967

Postpartum haemorrhage related early increase in D-dimers is inhibited by tranexamic acid: haemostasis parameters of a randomized controlled open labelled trial.

A S Ducloy-Bouthors1, A Duhamel2, E Kipnis1, A Tournoys3, A Prado-Dupont4, A Elkalioubie5, E Jeanpierre3, G Debize6, E Peynaud-Debayle7, D DeProst8, C Huissoud9, A Rauch3, S Susen10.   

Abstract

BACKGROUND: Beneficial effects of tranexamic acid (TA) have been established in surgery and trauma. In ongoing postpartum haemorrhage (PPH), a moderate reduction of blood loss was observed in a previously published randomized controlled trial. Analysis of haemostasis parameters obtained from samples collected as part of this study are presented.
METHODS: Women with PPH >800 ml after vaginal delivery were assigned to receive either TA (4 g over 1 h, then 1 g per h over six h) (TA) or not (H). A non-haemorrhagic group (NH), <800 ml blood loss, was included as postpartum reference. At four time-points (enrolment, +30 min, +2 h, +6 h), haemostasis was assessed. Haemostasis assays were performed blinded to group allocation. Data were expressed as median [interquartiles] and compared with non-parametric tests.
RESULTS: In H compared with NH group, D-dimers increase (3730 ng ml(-1) [2468-8493] vs 2649 [2667-4375]; P=0.0001) and fibrinogen and factor II decrease were observed at enrolment and became maximal 2 h later. When comparing TA to H patients, the increase in Plasmin-Antiplasmin-complexes at +30 min (486 ng ml(-1) [340-1116] vs 674 [548-1640]; P=0.03) and D-dimers at +2 h (3888 ng ml(-1) [2688-6172] vs 7495 [4400-15772]; P=0.0001) was blunted. TA had no effect on fibrinogen decrease.
CONCLUSIONS: This study provides biological evidence of an early increase in D-dimers and plasmin-antiplasmin complexes associated with active post-partum haemorrhage and its attenuation by the early use of a clinically effective high dose of TA, opening the perspective of dose ranging studies to determinate the optimal dose and timing in this setting. CLINICAL TRIAL REGISTRATION: ISRCTN09968140.
© The Author 2016. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  fibrinogen; fibrinolysis; postpartum haemorrhage; tranexamic acid

Mesh:

Substances:

Year:  2016        PMID: 27106967     DOI: 10.1093/bja/aew021

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  16 in total

1.  The expanding role of tranexamic acid in the management of obstetric hemorrhage.

Authors:  John T Sullivan
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

2.  Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.

Authors:  Peter A Kouides
Journal:  Blood Adv       Date:  2017-04-25

Review 3.  DIC in Pregnancy - Pathophysiology, Clinical Characteristics, Diagnostic Scores, and Treatments.

Authors:  Offer Erez; Maha Othman; Anat Rabinovich; Elad Leron; Francesca Gotsch; Jecko Thachil
Journal:  J Blood Med       Date:  2022-01-06

Review 4.  Peripartum Haemorrhage: Haemostatic Aspects of the New German PPH Guideline.

Authors:  Heiko Lier; Christian von Heymann; Wolfgang Korte; Dietmar Schlembach
Journal:  Transfus Med Hemother       Date:  2017-11-15       Impact factor: 3.747

Review 5.  Antifibrinolytic drugs for treating primary postpartum haemorrhage.

Authors:  Haleema Shakur; Danielle Beaumont; Sue Pavord; Angele Gayet-Ageron; Katharine Ker; Hatem A Mousa
Journal:  Cochrane Database Syst Rev       Date:  2018-02-20

6.  Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.

Authors:  Homa K Ahmadzia; Naomi L C Luban; Shuhui Li; Dong Guo; Adam Miszta; Jogarao V S Gobburu; Jeffrey S Berger; Andra H James; Alisa S Wolberg; John van den Anker
Journal:  Am J Obstet Gynecol       Date:  2020-11-26       Impact factor: 10.693

7.  TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.

Authors:  Anne-Sophie Ducloy-Bouthors; Emmanuelle Jeanpierre; Imen Saidi; Anne-Sophie Baptiste; Elodie Simon; Damien Lannoy; Alain Duhamel; Delphine Allorge; Sophie Susen; Benjamin Hennart
Journal:  Trials       Date:  2018-03-01       Impact factor: 2.279

8.  Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial.

Authors:  Anne-Sophie Bouthors; Benjamin Hennart; Emmanuelle Jeanpierre; Anne-Sophie Baptiste; Imen Saidi; Elodie Simon; Damien Lannoy; Alain Duhamel; Delphine Allorge; Sophie Susen
Journal:  Trials       Date:  2018-03-01       Impact factor: 2.279

9.  Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2017-04-26       Impact factor: 79.321

Review 10.  Bleeding Disorders in Primary Fibrinolysis.

Authors:  Massimo Franchini; Marco Zaffanello; Pier Mannuccio Mannucci
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.